Literature DB >> 10866139

Absorption, first-pass metabolism, and disposition of itraconazole in rats.

S D Yoo1, E Kang, H Jun, B S Shin, K C Lee, K H Lee.   

Abstract

This study examined the pharmacokinetic disposition, oral absorption and hepatic extraction of itraconazole and its active metabolite, hydroxyitraconazole, in rats. After i.v. injection, serum itraconazole concentrations decreased biexponentially, with an average terminal elimination half-life, volume of distribution and systemic clearance of 4.9 h, 6.0 l/kg and 14.2 ml/min/kg, respectively. When given orally, its absorption was low, with a mean absolute bioavailability of 16.6%. The metabolite to parent drug area under the curve (AUC) ratio was higher after oral administration compared with i.v. injection (mean ratio, 2.7 vs. 0.9). The hepatic drug extraction ratio determined after femoral and portal vein administration averaged 18.5%. When hydroxyitraconazole was injected i.v., the elimination half-life, volume of distribution and systemic clearance of itraconazole averaged 10.0 h, 2.4 l/kg and 3.4 ml/min/kg, respectively. The fraction of the systemically available itraconazole that was metabolized to hydroxyitraconazole was 21.0% and 76.0% after i.v. and oral administration, respectively. In summary, this study is the first reporting the hepatic extraction of itraconazole and the i.v. disposition characteristics of hydroxyitraconazole in rats. Itraconazole is a drug with a low hepatic extraction ratio and its systemic clearance appears to be largely accounted for by hepatic metabolism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10866139     DOI: 10.1248/cpb.48.798

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  7 in total

1.  Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect.

Authors:  Jee H Shin; Ka Y Choi; Yu C Kim; Myung G Lee
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

2.  Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.

Authors:  Eleanor J Guest; Karen Rowland-Yeo; Amin Rostami-Hodjegan; Geoffrey T Tucker; J Brian Houston; Aleksandra Galetin
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

3.  Comparative analysis of the effects of rice and bread meals on bioavailability of itraconazole using NONMEM in healthy volunteers.

Authors:  Hwi-yeol Yun; Min Sun Baek; In Sook Park; Bo Kyung Choi; Kwang-il Kwon
Journal:  Eur J Clin Pharmacol       Date:  2006-10-20       Impact factor: 2.953

4.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

5.  Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.

Authors:  Stefanie Hennig; Claire E Wainwright; Scott C Bell; Hugh Miller; Lena E Friberg; Bruce G Charles
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction.

Authors:  Yuan Chen; Fang Ma; Tong Lu; Nageshwar Budha; Jin Yan Jin; Jane R Kenny; Harvey Wong; Cornelis E C A Hop; Jialin Mao
Journal:  Clin Pharmacokinet       Date:  2016-06       Impact factor: 6.447

7.  Investigation of microemulsion system for transdermal delivery of itraconazole.

Authors:  Arpan Chudasama; Vineetkumar Patel; Manish Nivsarkar; Kamala Vasu; Chamanlal Shishoo
Journal:  J Adv Pharm Technol Res       Date:  2011-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.